Can a drug that blocks HER proteins re-sensitize resistant breast cancer to hormone therapy?
NCT ID NCT07729046
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive either standard care alone or standard care plus daily neratinib. The study aims to see if the combination extends the time before the cancer progresses and to assess side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- neratinib plus standard endocrine therapy
- What this could lead to
- If it works, this could offer a new treatment option for people with metastatic breast cancer that has stopped responding to standard hormone therapy.
- What could go wrong
- This is a mid-stage trial, so the added benefit is uncertain. Neratinib can cause side effects like diarrhea, and the combination may not improve outcomes for all participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+, HER2-, METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UC San Diego Health Moores Cancer Center
La Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test reveal hidden breast cancer spread?
- Blood test could signal when to switch breast cancer therapy before tumors grow
- Blood markers may reveal hormone therapy success in breast cancer
- Blood test could match resistant breast cancer to best drug
- Breast cancer drug study looks at body fat changes
- Zapping resistant tumors: could radiation keep breast cancer therapy working longer?